238 related articles for article (PubMed ID: 25184229)
1. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.
Siegel DS
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229
[No Abstract] [Full Text] [Related]
2. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Shah JJ
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
4. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Nooka AK
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Martin TG
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
7. Management of Carfilzomib-Associated Cardiac Adverse Events.
Mikhael J
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
[TBL] [Abstract][Full Text] [Related]
9. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Wang M; Cheng J
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():24-30. PubMed ID: 25184233
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
12. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib.
Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F
Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833
[TBL] [Abstract][Full Text] [Related]
13. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
Sandy EB; Weerasinghe C; Terjanian T
J Pharm Pract; 2020 Apr; 33(2):213-216. PubMed ID: 30278813
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
[TBL] [Abstract][Full Text] [Related]
16. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M; Bonello F; Boccadoro M; Larocca A
Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
[TBL] [Abstract][Full Text] [Related]
17. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials.
Wongsaengsak S; Kopel J; Behera TR; Chakraborty R; Ball S
Br J Haematol; 2020 Jul; 190(2):e95-e97. PubMed ID: 32400886
[No Abstract] [Full Text] [Related]
18. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
Tjionas H; Gupta AK
J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028
[TBL] [Abstract][Full Text] [Related]
19. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.
Gavazzoni M; Lombardi CM; Vizzardi E; Gorga E; Sciatti E; Rossi L; Belotti A; Rossi G; Metra M; Raddino R
Eur J Pharmacol; 2018 Nov; 838():85-90. PubMed ID: 30201379
[TBL] [Abstract][Full Text] [Related]
20. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
